These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 10337502)

  • 21. Evaluation of the therapeutic efficacy and tolerability of levocarnitine propionyl in the treatment of chronic obstructive arteriopathies of the lower extremities: a multicentre controlled study vs. placebo.
    Coto V; D'Alessandro L; Grattarola G; Imparato L; Lingetti M; Mancini M; Nolfe G; Rengo F
    Drugs Exp Clin Res; 1992; 18(1):29-36. PubMed ID: 1600865
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A study on the efficacy and safety assessment of propionyl-L-carnitine tablets in treatment of intermittent claudication.
    Luo T; Li J; Li L; Yang B; Liu C; Zheng Q; Jin B; Chen Z; Li K; Zhang X; Zhang J
    Thromb Res; 2013 Oct; 132(4):427-32. PubMed ID: 23998557
    [TBL] [Abstract][Full Text] [Related]  

  • 23. 31Phosphorus magnetic resonance spectroscopy to evaluate medical therapy efficacy in peripheral arterial disease. A pilot study.
    Di Marzo L; Miccheli A; Sapienza P; Tedesco M; Mingoli A; Capuani G; Aureli T; Giuliani A; Conti F; Cavallaro A
    Panminerva Med; 1999 Dec; 41(4):283-90. PubMed ID: 10705707
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of defibrotide on physical performance and hemorheologic picture in patients with peripheral arteriopathy.
    Marrapodi E; Leanza D; Giordano S; Nazzari M; Corsi C
    Clin Trials Metaanal; 1994 Apr; 29(1):21-30. PubMed ID: 10150182
    [TBL] [Abstract][Full Text] [Related]  

  • 25. European multicenter study on propionyl-L-carnitine in intermittent claudication.
    Brevetti G; Diehm C; Lambert D
    J Am Coll Cardiol; 1999 Nov; 34(5):1618-24. PubMed ID: 10551714
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Oral buflomedil in the prevention of cardiovascular events in patients with peripheral arterial obstructive disease: a randomized, placebo-controlled, 4-year study.
    ; Leizorovicz A; Becker F
    Circulation; 2008 Feb; 117(6):816-22. PubMed ID: 18212283
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Superiority of L-propionylcarnitine vs L-carnitine in improving walking capacity in patients with peripheral vascular disease: an acute, intravenous, double-blind, cross-over study.
    Brevetti G; Perna S; Sabbà C; Rossini A; Scotto di Uccio V; Berardi E; Godi L
    Eur Heart J; 1992 Feb; 13(2):251-5. PubMed ID: 1555624
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Double-blind randomized comparative study of nicergoline naftidrofuryl on the quality of life in chronic obliterative arteriopathy of lower limbs with intermittent claudication].
    Meilhac B; Montestruc F; Aubin F; Djian F; Rouffy J
    Therapie; 1997; 52(3):179-86. PubMed ID: 9366101
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A double-blind, placebo-controlled multicentre trial of ticlopidine in patients with peripheral arterial disease in Argentina. Design, organization and general characteristics of patients at entry. The EMATAP Group.
    Blanchard JF; Carreras LO
    Nouv Rev Fr Hematol (1978); 1992; 34(2):149-53. PubMed ID: 1502021
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Trial of a novel prostacyclin analog, UT-15, in patients with severe intermittent claudication.
    Mohler ER; Klugherz B; Goldman R; Kimmel SE; Wade M; Sehgal CM
    Vasc Med; 2000; 5(4):231-7. PubMed ID: 11213235
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [MR-Imaging of lower leg muscle perfusion].
    Leppek R; Hoos O; Sattler A; Kohle S; Azzam S; Al Haffar I; Keil B; Ricken P; Klose KJ; Alfke H
    Herz; 2004 Feb; 29(1):32-46. PubMed ID: 14968340
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Heparan sulphate in association with indobufen in the treatment of chronic peripheral obliterative arteriopathy of the lower extremities. Controlled clinical trial].
    Rossini A; Tascino C; Costa F
    Minerva Cardioangiol; 1998 Nov; 46(11):457-69. PubMed ID: 10207294
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [A new therapeutic proposal for intermittent claudication. Propionyl-L-carnitine: new indications concerning mechanism of action].
    Brevetti G; Martone VD; Corrado S; Silvestro A; Di Donato AM; Di Iorio A
    Minerva Cardioangiol; 1998 Sep; 46(9):299-300. PubMed ID: 10021852
    [No Abstract]   [Full Text] [Related]  

  • 34. Propionyl-L-carnitine therapy: effects on endothelin-1 and homocysteine levels in patients with peripheral arterial disease and end-stage renal disease.
    Signorelli SS; Fatuzzo P; Rapisarda F; Neri S; Ferrante M; Oliveri Conti G; Fallico R; Di Pino L; Pennisi G; Celotta G; Anzaldi M
    Kidney Blood Press Res; 2006; 29(2):100-7. PubMed ID: 16809937
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Hyper- or isovolemic hemodilution in patients with stage II peripheral arterial occlusive disease].
    Kiesewetter H; Jung F; Blume J; Spitzer S; Birk A
    Acta Med Austriaca; 1991; 18 Suppl 1():23-7. PubMed ID: 1719729
    [TBL] [Abstract][Full Text] [Related]  

  • 36. START Trial: a pilot study on STimulation of ARTeriogenesis using subcutaneous application of granulocyte-macrophage colony-stimulating factor as a new treatment for peripheral vascular disease.
    van Royen N; Schirmer SH; Atasever B; Behrens CY; Ubbink D; Buschmann EE; Voskuil M; Bot P; Hoefer I; Schlingemann RO; Biemond BJ; Tijssen JG; Bode C; Schaper W; Oskam J; Legemate DA; Piek JJ; Buschmann I
    Circulation; 2005 Aug; 112(7):1040-6. PubMed ID: 16087795
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of L-propionyl carnitine on in-vitro membrane alteration of sickle-cell anaemia erythrocytes.
    Ronca F; Palmieri L; Malengo S; Bertelli A
    Int J Tissue React; 1994; 16(4):187-94. PubMed ID: 7797405
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Prostacyclin and pentoxifylline in the treatment of patients with inoperable occlusions of the peripheral arteries of the lower extremities].
    Maksimović ZV
    Srp Arh Celok Lek; 1999; 127(7-8):249-53. PubMed ID: 10624398
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treadmill exercise-induced release of endothelin-1 in patients with peripheral arterial occlusive disease at Fontaine stage IIb.
    Mangiafico RA; Malatino LS; Spada RS; Santonocito M; Messina R; Dell'Arte S; Attinà T
    Int Angiol; 2000 Mar; 19(1):14-7. PubMed ID: 10853680
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of propionyl-L-carnitine on quality of life in intermittent claudication.
    Brevetti G; Perna S; Sabba C; Martone VD; Di Iorio A; Barletta G
    Am J Cardiol; 1997 Mar; 79(6):777-80. PubMed ID: 9070558
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.